Results 141 to 150 of about 1,716,389 (207)

Mucosal immunity and vaccine development. [PDF]

Signal Transduct Target Ther
Hong W, Alu A, Zhang Z, Zhang Y, He X, Xu L, Li M, He W, Wang J.   +8 more
europepmc   +1 more source

Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda. [PDF]

Nat Microbiol
Tushabe P, Majumdar M, Carlyle S, Shulman L, Ssekagiri A, Joffret ML, Klapsa D, Cremer J, Arowolo KO, Bujaki E, Bukenya H, EPI Laboratory team, Nanteza MB, Turyahabwe I, Namuwulya P, Birungi M, Eliku JP, Aine F, Tibanagwa M, Nakabazzi L, Gaizi J, Ssebuuma AM, Dhatemwa R, Okia C, Nyachwo M, Nanteza MB, Turyahabwe I, Namuwulya P, Birungi M, Eliku JP, Aine F, Tibanagwa M, Nakabazzi L, Gaizi J, Ssebuuma AM, Dhatemwa R, Okia C, Nyachwo M, Hawes KM, Bakamutumaho B, Duizer E, Bessaud M, Bandyopadhyay AS, Macadam A, Byabamazima CR, Martin J, Bwogi J.   +46 more
europepmc   +1 more source

Towards Global HPV Eradication: Single-Dose HPV Vaccination vs. Pseudoscience. [PDF]

Pathophysiology
Shiro R, Tsunoda I.
europepmc   +1 more source

Rotavirus mucosal immunology: insights and research priorities from an international convening in Liverpool, March 2024. [PDF]

NPJ Vaccines
Bronowski C, Mwendera CA, Kirkwood CD, Steele AD, Groome MJ, Jere KC.   +5 more
europepmc   +1 more source

Uncovering the spatiotemporal patterns of the largest vaccine-derived poliovirus serotype 2 outbreak in the Democratic Republic of the Congo

Candido DdS, Chopra K, Mampuela TK, Shaw A, Jorgensen D, Martin J, Pratt C, Lofiko E, Lemey P, Riziki Y, Grassly N, Mbala P, Blake I.   +12 more
europepmc   +1 more source

The long-term impact and effectiveness of rotavirus vaccination in Malawi: an interrupted time-series and case-control analysis

Ndeketa L, Pitzer VE, Jere KC, Bennett A, Cunliffe NA, Dodd PJ, French N, Hungerford D.   +7 more
europepmc   +1 more source

Modeling the Potential Role of Inactivated Poliovirus Vaccine to Manage the Risks of Oral Poliovirus Vaccine Cessation

Journal of Infectious Diseases, 2014
Background: The Global Polio Eradication Initiative plans to stop all oral poliovirus vaccine (OPV) after wild poliovirus eradication, starting with serotype 2.
Kimberly M Thompson, Radboud Duintjer Tebbens, Duintjer Tebbens Radboud J   +2 more
exaly   +3 more sources

Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study

Lancet, The, 2007
BACKGROUND: A high-potency monovalent oral type 1 poliovirus vaccine (mOPV1) was developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected countries. Our aim was to assess the efficacy of this vaccine in India. METHODS:
Jagadish Deshpande, Nicholas Grassly, Roland W Sutter   +2 more
exaly   +2 more sources